Research update for articles published in EJCI in 2010

Abstract

Recently [1]Winkler et al. [2] reported that total cholesterol, LDL-C and small, dense LDL (sdLDL) were significantly reduced with ezetimibe 10 mg (E10), simvastatin 20 mg (S20) and the combination of E10 ⁄ S20 in patients with type 2 diabetes and a preponderance of sdLDL. The further decrease of sdLDL by adding ezetimibe to simvastatin was not significant. Florentin et al. [3] showed that S10 plus E10 is similarly effective to S40 in improving sdLDL and LDL particle size in patients with primary hypercholesterolaemia. In the study of Berneis et al. [4], healthy men were treated with Recent clinical [42] studies have largely confirmed the association between increased FGF21 levels and the presence of nonalcoholic fatty liver disease (NAFLD). In addition, the evidence that FGF21 chiefly mirrors the extent of hepatic steatosis has reinforced. In this regard, Li et al. [43] reported that serum

Prognostic relevance of BRD7 expression in colorectal carcinoma

“…Colorectal cancer (CRC) is among the most frequently diagnosed cancer with more than 1 million new cases occurred every year worldwide and the second leading cause of cancer death in developed countries [1,2]. Despite recent advances in the clinical treatment of CRC [3][4][5][6], patients with metastatic CRC still have poor prognosis [7]. Clinical stage based on TNM classification system at diagnosis remains the most remarkable prognosis factor up to present [8], and the molecular mechanism involved in development and progression of CRC remains unclear [9].…”